Anterior cingulate cortex activity during attentional control corresponds with rumination in depression and social anxiety

2021 ◽  
Vol 317 ◽  
pp. 111385
Author(s):  
Michelle K. Sheena ◽  
Jagan Jimmy ◽  
Katie L. Burkhouse ◽  
Heide Klumpp
Keyword(s):  
Social Anxiety ◽  
Anterior Cingulate Cortex ◽  
Attentional Control ◽  
Cingulate Cortex ◽  
Anterior Cingulate ◽  
Anterior Cingulate Cortex Activity

INTERACTION BETWEEN DARPP-32 AND DRD2 GENETIC VARIANTS ON ANTERIOR CINGULATE CORTEX ACTIVITY DURING ATTENTIONAL CONTROL IN HEALTHY SUBJECTS

2010 ◽  
Vol 117 (2-3) ◽  
pp. 472
Author(s):  
Paolo Taurisano ◽  
Giuseppe Blasi ◽  
Apostolos Papazacharias ◽  
Raffaella Romano ◽  
Gianluca Ursini ◽  
...  
Keyword(s):  
Anterior Cingulate Cortex ◽  
Genetic Variants ◽  
Attentional Control ◽  
Healthy Subjects ◽  
Cingulate Cortex ◽  
Anterior Cingulate ◽  
Anterior Cingulate Cortex Activity

scholarly journals Anterior cingulate cortex activity as a candidate biomarker for treatment selection in social anxiety disorder

BJPsych Open ◽  
2018 ◽  
Vol 4 (3) ◽  
pp. 157-159 ◽  
Author(s):  
Andreas Frick ◽  
Jonas Engman ◽  
Kurt Wahlstedt ◽  
Malin Gingnell ◽  
Mats Fredrikson ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Anterior Cingulate Cortex ◽  
Social Anxiety Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Cingulate Cortex ◽  
Demographic Variables ◽  
Treatment Selection ◽  
Anterior Cingulate ◽  
Potential Biomarker

SummaryWe aimed to identify biomarkers to guide the decision to add selective serotonin reuptake inhibitors (SSRI) to psychological treatment for social anxiety disorder (SAD). Forty-eight patients with SAD underwent functional magnetic resonance imaging and collection of clinical and demographic variables before treatment with cognitive–behavioural therapy, combined on a double-blind basis with either escitalopram or placebo for 9 weeks. Pre-treatment neural reactivity to aversive faces in the dorsal anterior cingulate cortex (ACC), but not clinical/demographic variables, moderated clinical outcomes. Cross-validated individual-level predictions accurately identified 81% of responders/non-responders. Dorsal ACC reactivity is thus a potential biomarker for SAD treatment selection.Declaration of interestNone.

Sign in / Sign up

Export Citation Format

Share Document